AstraZeneca commissioned CRA to investigate the economic and societal burden associated with Acute Coronary Syndromes (ACS). Our Life Sciences specialists analyzed occurrences of ACS in the United Kingdom, treatment cost of ACS in the United Kingdom, economic cost of ACS, and the total burden of disease associated with ACS. This short paper represents a summary of the full report.
Life sciences considerations for investment treaty disputes
Greg Bell, Andrew Tepperman, and Justin Ho co-authored a chapter in the ninth edition of The Investment Treaty Arbitration Review. The chapter titled...